Jefferies on Thursday launched its coverage of oncology-focused biotech Verastem (NASDAQ:VSTM) with a Buy rating and $15 per share target, citing a potential FDA nod for its ovarian cancer drug combo ...

In early 2021 Joss Cook began suffering from abdominal pains, bloating, needed to urinate more and quickly felt full when ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

To optimize treatment outcomes for patients whose late-stage cancer shows resistance to the standard treatment, Sarasota Memorial Research Institute will participate in testing an experimental ...

Results from a new Phase 3 trial published in the journal npj Precision Oncology found that a cancer stem cell test can ...

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

Inside the Reproductive Sciences Lab at the University of Colorado Anschutz Medical Campus in Aurora, researchers are on the ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

If you've spent anytime commuting around the Baltimore area, chances are you've heard of Brick Bodies. The local family owned ...

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...